Expert Commentary on Wakefield,T.W.: The Safety,Efficacy,and Cost Efficiency of Outpatient Treatment of Acute Deep Venous Thrombosis with Low Molecular Weight Heparin (pp. 19-26)

Dunn AS , Coller B. Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med 1999;106:660-669

Boccalon H. , Elias A. , Chalé J-J. , Cadène A. , Gabriel S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight- heparin. Arch Intern Med 2000:160:1769-1773

Canada T. Emerging roles of low-molecular-weight heparin derivatives in anticoagulation . http://www.InetCE.org/articles/146-000-99-003-H01.html

Salartash K. , Lepore M. , Gonze MD , Leone-Bay A. , Baughman R. , Sternbergh W. , Bowen JC , Money SR Treatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis. Ann Surg 2000;231:789-794

Gonze MD , Salartash K. , Sternbergh WC , Baughman RA , Leone-Bay A. , Money SR Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation 2000 ;101:2658-2661